MX2023014866A - Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas. - Google Patents
Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas.Info
- Publication number
- MX2023014866A MX2023014866A MX2023014866A MX2023014866A MX2023014866A MX 2023014866 A MX2023014866 A MX 2023014866A MX 2023014866 A MX2023014866 A MX 2023014866A MX 2023014866 A MX2023014866 A MX 2023014866A MX 2023014866 A MX2023014866 A MX 2023014866A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- engineered
- car
- host
- methods
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title 1
- 230000002688 persistence Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 abstract 1
- 108010065524 CD52 Antigen Proteins 0.000 abstract 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 abstract 1
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente descripción se proporcionan proteínas de unión a CD70 que comprenden un dominio de unión a CD70 y un dominio transmembranario, células inmunitarias genomanipuladas que comprenden las proteínas de unión a CD70, y métodos para fabricarlas y usarlas. También se proporcionan en la presente descripción células inmunitarias genomanipuladas, p. ej., células T con CAR (receptor quimérico para el antígeno) para la administración a pacientes para tratar el cáncer (p. ej., tumores sólidos y tumores hematológicos) y otras afecciones no deseadas. Las células se genomanipulan para expresar funcionalmente una primera molécula de unión a antígenos, p. ej., un CAR de CD70 y una segunda molécula de unión a antígenos, p. ej., un segundo CAR que se une a una molécula diana característica del cáncer u otra enfermedad o afección no deseada. Las células pueden genomanipularse además para reducir el nivel de expresión funcional de uno o más de TRAC, CD52 y CD70. También se proporcionan métodos para fabricar y usar las células genomanipuladas, composiciones y kits que las comprenden, y métodos para tratar mediante su administración.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163210979P | 2021-06-15 | 2021-06-15 | |
| US202263351223P | 2022-06-10 | 2022-06-10 | |
| PCT/US2022/033598 WO2022266203A1 (en) | 2021-06-15 | 2022-06-15 | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014866A true MX2023014866A (es) | 2024-01-16 |
Family
ID=82608367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014866A MX2023014866A (es) | 2021-06-15 | 2022-06-15 | Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220409665A1 (es) |
| EP (1) | EP4355358A1 (es) |
| JP (1) | JP2024526090A (es) |
| KR (1) | KR20240021826A (es) |
| AU (1) | AU2022292640A1 (es) |
| BR (1) | BR112023026249A2 (es) |
| CA (1) | CA3221957A1 (es) |
| IL (1) | IL308468A (es) |
| MX (1) | MX2023014866A (es) |
| WO (1) | WO2022266203A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202440623A (zh) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途 |
| WO2025096594A2 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ES2302726T3 (es) | 2000-02-24 | 2008-08-01 | Invitrogen Corporation | Estimulacion y concentracion simultanea de celulas. |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
| WO2013176915A1 (en) | 2012-05-25 | 2013-11-28 | Roman Galetto | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| ES2869972T3 (es) | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| AU2018367449B2 (en) * | 2017-11-14 | 2024-06-13 | Memorial Sloan-Kettering Cancer Center | IL-33 secreting immunoresponsive cells and uses thereof |
| BR112020015662A2 (pt) * | 2018-02-01 | 2020-12-08 | Pfizer Inc. | Receptores de antígeno quimérico direcionados a cd70 |
| US20220411478A1 (en) * | 2019-09-16 | 2022-12-29 | The General Hospital Corporation | Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof |
| WO2022129216A1 (en) * | 2020-12-15 | 2022-06-23 | Universiteit Antwerpen | Cell-based therapeutics targeting cd70 |
-
2022
- 2022-06-15 KR KR1020237043896A patent/KR20240021826A/ko active Pending
- 2022-06-15 US US17/841,041 patent/US20220409665A1/en active Pending
- 2022-06-15 EP EP22743976.7A patent/EP4355358A1/en active Pending
- 2022-06-15 MX MX2023014866A patent/MX2023014866A/es unknown
- 2022-06-15 CA CA3221957A patent/CA3221957A1/en active Pending
- 2022-06-15 JP JP2023577355A patent/JP2024526090A/ja active Pending
- 2022-06-15 AU AU2022292640A patent/AU2022292640A1/en active Pending
- 2022-06-15 IL IL308468A patent/IL308468A/en unknown
- 2022-06-15 BR BR112023026249A patent/BR112023026249A2/pt unknown
- 2022-06-15 WO PCT/US2022/033598 patent/WO2022266203A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022292640A1 (en) | 2023-11-30 |
| WO2022266203A1 (en) | 2022-12-22 |
| KR20240021826A (ko) | 2024-02-19 |
| AU2022292640A9 (en) | 2023-12-14 |
| IL308468A (en) | 2024-01-01 |
| BR112023026249A2 (pt) | 2024-03-05 |
| CA3221957A1 (en) | 2022-12-22 |
| JP2024526090A (ja) | 2024-07-17 |
| US20220409665A1 (en) | 2022-12-29 |
| EP4355358A1 (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230081443A1 (en) | Anti-il1rap antibodies | |
| RU2624049C2 (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| CN106661129B (zh) | 对ssea4抗原具有特异性的嵌合抗原受体 | |
| WO2021053667A2 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
| MX2023014866A (es) | Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas. | |
| CN114729040A (zh) | 抗tigit抗体 | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| US20200325212A1 (en) | Tumor-selective ctla-4 antagonists | |
| CN105407922A (zh) | 涉及癌症干细胞的癌症的诊断与治疗 | |
| US20230312708A1 (en) | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers | |
| US20170058043A1 (en) | Bispecific antibody for cancer immunotherapy | |
| AR121921A1 (es) | Composiciones y métodos de tratamiento del cáncer con receptores de antígeno quimérico | |
| EP4061848A1 (en) | Anti-ror-2 antibodies and methods of use | |
| BR112019026172A2 (pt) | uso de uma célula-tronco mesenquimal | |
| US20240400686A1 (en) | Anti-cd3 antibodies and uses thereof | |
| JP7678493B2 (ja) | 癌関連免疫抑制阻害剤 | |
| US20260008864A1 (en) | Bispecific anti-cd38-cd3 binders | |
| AR132064A1 (es) | Anticuerpos anti-cldn6 y métodos de uso | |
| CA3151815A1 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| JP7357347B2 (ja) | 細胞外のＰＫＣδを標的とする肝癌細胞増殖抑制剤及びそれを含む新規肝癌治療薬 | |
| MX2023014836A (es) | Proteínas de unión anti-ctla-4 y métodos de uso de estas. | |
| US20240317873A1 (en) | Anti-hvem antibodies | |
| AR132062A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso | |
| Diamantoudis et al. | Assessing the Hematological Cancer Stem Cell Landscape to Improve Immunotherapy Clinical Decisions |